Profile data is unavailable for this security.
About the company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
- Revenue in USD (TTM)0.00
- Net income in USD-125.32m
- Incorporated2010
- Employees57.00
- LocationMind Medicine (MindMed) IncOne World Trade Center, Suite 8500NEW YORK 10007United StatesUSA
- Phone+1 (212) 220-6633
- Fax+1 (888) 848-3972
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kyverna Therapeutics Inc | 0.00 | -75.92m | 574.73m | 100.00 | -- | 1.59 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
Avid Bioservices Inc | 136.74m | -17.96m | 577.03m | 365.00 | -- | 3.20 | -- | 4.22 | -0.284 | -0.284 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -3.97 | 10.73 | -6.03 | 15.22 | 7.47 | 22.72 | -13.13 | 25.92 | 0.3097 | -5.04 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
Erasca Inc | 0.00 | -126.86m | 580.68m | 126.00 | -- | 1.28 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -106.80m | 583.01m | 33.00 | -- | 4.92 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
PetIQ Inc | 1.12bn | 7.34m | 591.47m | 1.93k | 92.20 | 2.50 | 10.90 | 0.5281 | 0.2156 | 0.2156 | 36.40 | 7.95 | 1.29 | 4.58 | 5.67 | 579,376.60 | 0.8933 | -4.32 | 1.14 | -5.23 | 23.66 | 20.05 | 0.6951 | -3.66 | 1.25 | 1.84 | 0.6517 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 597.41m | 121.00 | -- | 2.29 | -- | 11.94 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
Savara Inc | 0.00 | -64.49m | 598.36m | 37.00 | -- | 4.91 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 603.61m | 285.00 | -- | 1.42 | -- | 261.19 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 603.73m | 57.00 | -- | 3.05 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 605.84m | 452.00 | -- | -- | -- | 233.55 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
Third Harmonic Bio Inc | 0.00 | -29.60m | 607.87m | 31.00 | -- | 2.28 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Harrow Inc | 138.68m | -31.33m | 609.28m | 315.00 | -- | 10.06 | -- | 4.39 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
SNDL Inc | 660.41m | -99.67m | 609.55m | 2.52k | -- | 0.6905 | -- | 0.923 | -0.3807 | -0.3895 | 2.53 | 3.39 | 0.5855 | 4.67 | 33.35 | 262,485.40 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 618.26m | 102.00 | -- | 1.88 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Mineralys Therapeutics Inc | 0.00 | -90.80m | 621.60m | 28.00 | -- | 1.89 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Exscientia PLC (ADR) | 24.93m | -164.44m | 624.29m | 483.00 | -- | 1.49 | -- | 25.04 | -1.30 | -1.30 | 0.1973 | 3.33 | 0.0364 | -- | 34.98 | 51,618.34 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Deep Track Capital LPas of 31 Mar 2024 | 6.67m | 9.46% |
Commodore Capital LPas of 31 Mar 2024 | 5.83m | 8.27% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 2.55m | 3.61% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 2.15m | 3.05% |
Great Point Partners LLCas of 31 Mar 2024 | 2.00m | 2.84% |
Marshall Wace LLPas of 31 Mar 2024 | 2.00m | 2.84% |
Blackstone Alternative Asset Management LPas of 31 Mar 2024 | 1.25m | 1.77% |
Woodline Partners LPas of 31 Mar 2024 | 1.00m | 1.42% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 955.68k | 1.36% |
AWM Investment Co., Inc.as of 31 Mar 2024 | 833.00k | 1.18% |